Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026)
Ocugen (OCGN) posted Net Income towards Common Stockholders of -$19.2 million for Q1 2026, down 24.93% on a QoQ basis from -$15.4 million in Q1 2025, and down 24.93% year-over-year from -$25.5 million in Q1 2025.
Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Ocugen's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$19.2 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 24.93% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.2 million (down 232.79% YoY) and the FY2024 annual result came in at -$44000.0, up 99.93% from the prior year.
- Net Income towards Common Stockholders was -$19.2 million for Q1 2026 at Ocugen, down from -$15.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $40.1 million in Q4 2024 and bottomed at -$63.1 million in Q4 2023.
- A 5-year average of -$19.2 million and a median of -$21.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 187.52% — and 2024, when it surged 163.55%.
- Ocugen's Net Income towards Common Stockholders stood at -$21.9 million in 2022, then plunged by 187.52% to -$63.1 million in 2023, then jumped by 163.55% to $40.1 million in 2024, then sank by 138.29% to -$15.4 million in 2025, then retreated by 24.93% to -$19.2 million in 2026.
- Business Quant data shows OCGN's Net Income towards Common Stockholders at -$19.2 million in Q1 2026, -$15.4 million in Q1 2025, and $40.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Ocugen | 415.98 Mn | 415.98 Mn | - | -19.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.18 Mn |
| Mar 31, 2025 | -15.35 Mn |
| Dec 31, 2024 | 40.08 Mn |
| Jun 30, 2024 | -10.29 Mn |
| Dec 31, 2023 | -63.08 Mn |
| Sep 30, 2023 | -11.72 Mn |
| Jun 30, 2023 | -23.07 Mn |
| Mar 31, 2023 | -22.85 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -27.15 Mn |
| Mar 31, 2022 | -33.50 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |
| Jun 30, 2021 | -25.95 Mn |
| Mar 31, 2021 | -56.66 Mn |
| Dec 31, 2020 | -3.79 Mn |
| Sep 30, 2020 | -10.47 Mn |
| Jun 30, 2020 | -16.16 Mn |
| Mar 31, 2020 | -3.99 Mn |